• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·LLY
Held by 4 Gurus
Share

Eli Lilly and Company Stocks

$ 1124.21Last Updated 09.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 1.06T

$ 1124.21
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.8%

Change

+0.25%

Fund

CITADEL ADVISORS LLC

Cathie Wood

Portfolio Weight (%)

0.6%

Change

+0.51%

Fund

ARK Investment Management LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.4%

Change

+0.14%

Fund

Bridgewater Associates

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.8%+0.25%
Cathie WoodARK Investment Management LLC0.6%+0.51%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.4%+0.14%
Show more

Latest news

01.09.2026 02:38

Eli Lilly has found a new acquisition target. The company has already spent $20 billion this year

17.08.2026 17:07

Motley Fool sees big risks and big upside in anti-obesity drugmakers Viking, Kailera

05.08.2026 23:41

Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline

05.08.2026 15:41

Morning in New York: Market News Will Exacerbate Volatility

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of LLY is 1225 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 01:04

Brent crude at $108 fueled expectations of a Fed rate hike. U.S. stocks fell

11.09.2026 00:14

The trader who predicted "Black Monday" compared AI to a "Category 6 hurricane"

10.09.2026 22:51

Anthropic has caught its leading Chinese competitors secretly using Claude

10.09.2026 21:55

JPMorgan recommended buying Meta shares: its new AI assistant has strengthened its position

10.09.2026 21:24

The owner of Vimeo has agreed to acquire Miro, a company with Russian roots, for $1.4 billion

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026